Redigerer Anakinra (avsnitt)

== Litteratur ==
* {{Literatur
   |Autor=Ernst Mutschler et al.
   |Titel=Mutschler - Arzneimittelwirkungen, Pharmakologie Klinische Pharmakologie Toxikologie
   |Auflage=11.
   |Verlag=Wissenschaftl. Verlagsgesellschaft
   |Ort=Stuttgart
   |Datum=2020
   |ISBN=978-3-8047-3663-4
   |Seiten=803-804}}
* {{cite journal |author=Singh JA, Christensen R, Wells GA, ''et al.'' |title=Biologics for rheumatoid arthritis: an overview of Cochrane reviews |journal=Cochrane Database Syst Rev |volume= |issue=4 |pages=CD007848 |year=2009 |pmid=19821440 |doi=10.1002/14651858.CD007848.pub2}}
* {{cite journal |author=Cohen SB, et al. |title=A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret<sup>®</sup>), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background Methotrexate |journal=[[Ann Rheum Dis]] |volume=63 |issue=9 |pages=1062–1068 |year=2004 |pmid= |doi=10.1136/ard.2003.016014 |url=http://ard.bmj.com/content/63/9/1062.full}}
* Bresnihan B and Cobby M: ''Clinical and radiological effects of Anakinra in patients with rheumatoid arthritis.'' In: ''[[Rheumatology]]'', 2003 May;42(Suppl 2):ii22–ii28, [[doi:10.1093/rheumatology/keg329]].
* Konttinen L, et al. ''Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study.'' In: ''Clin Rheumatol'', 2006 Nov;25(6):882-884, [[doi:10.1007/s10067-006-00243-0]].
* Singh JA, et al. ''Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review).'' In: ''Cochrane Database Syst Rev'', 2011 Feb 16;(2):CD008794, [[doi:10.1002/14651858.CD008794.pub2]].

{{Autoritetsdata}}

[[Kategori:Legemidler]]
[[Kategori:Medikamentbruk mot covid-19]]